Eduardo Pimenta1, Michael Stowasser2, Richard D Gordon2, Susan M Harding3, Michel Batlouni4, Bin Zhang5, Suzanne Oparil6, David A Calhoun7. 1. Endocrine Hypertension Research Centre and Clinical Centre of Research Excellence in Cardiovascular Disease and Metabolic Disorders, The School of Medicine, The University of Queensland, Princess Alexandra and Greenslopes Private Hospitals, Brisbane, QLD, Australia; Dante Pazzanese Institute of Cardiology, São Paulo, Brazil. 2. Endocrine Hypertension Research Centre and Clinical Centre of Research Excellence in Cardiovascular Disease and Metabolic Disorders, The School of Medicine, The University of Queensland, Princess Alexandra and Greenslopes Private Hospitals, Brisbane, QLD, Australia. 3. Sleep/Wake Disorders Center, Division of Pulmonary, Allergy and Critical Care Medicine, Birmingham, AL. 4. Dante Pazzanese Institute of Cardiology, São Paulo, Brazil. 5. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 6. Vascular Biology and Hypertension Program, The University of Alabama at Birmingham, Birmingham, AL. 7. Sleep/Wake Disorders Center, Division of Pulmonary, Allergy and Critical Care Medicine, Birmingham, AL; Vascular Biology and Hypertension Program, The University of Alabama at Birmingham, Birmingham, AL. Electronic address: dcalhoun@uab.edu.
Abstract
BACKGROUND: Obstructive sleep apnea (OSA) is a strong and independent risk factor for the development of hypertension, particularly resistant hypertension, and cardiovascular diseases. Patients with resistant hypertension have a high prevalence of OSA in association with elevated aldosterone levels, high salt intake, and salt-sensitive BP. The objective of this study was to determine whether dietary salt and aldosterone are associated with severity of OSA in patients with resistant hypertension. METHODS: Ninety-seven patients with resistant hypertension were prospectively evaluated by overnight polysomnography and 24-h urinary sodium and aldosterone levels while maintaining their usual diet. Hyperaldosteronism was defined as a plasma renin activity of < 1 ng/mL/h and urinary aldosterone level of ≥ 12 μg/24 h. RESULTS: Overall, patients' mean clinic BP was 156.3 ± 22.4/88.9 ± 13.3 mm Hg while taking an average of 4.3 ± 1.1 antihypertensive medications. Prevalence of OSA was 77.3%. Twenty-eight (28.9%) patients had hyperaldosteronism. Urinary sodium level was an independent predictor of severity of OSA only in patients with hyperaldosteronism. CONCLUSIONS: The findings suggest that dietary salt is related to the severity of OSA in patients with resistant hypertension and hyperaldosteronism. The results support dietary salt restriction as a treatment strategy for reduction of OSA severity in these patients.
BACKGROUND:Obstructive sleep apnea (OSA) is a strong and independent risk factor for the development of hypertension, particularly resistant hypertension, and cardiovascular diseases. Patients with resistant hypertension have a high prevalence of OSA in association with elevated aldosterone levels, high salt intake, and salt-sensitive BP. The objective of this study was to determine whether dietary salt and aldosterone are associated with severity of OSA in patients with resistant hypertension. METHODS: Ninety-seven patients with resistant hypertension were prospectively evaluated by overnight polysomnography and 24-h urinary sodium and aldosterone levels while maintaining their usual diet. Hyperaldosteronism was defined as a plasma renin activity of &lt; 1 ng/mL/h and urinary aldosterone level of ≥ 12 μg/24 h. RESULTS: Overall, patients' mean clinic BP was 156.3 ± 22.4/88.9 ± 13.3 mm Hg while taking an average of 4.3 ± 1.1 antihypertensive medications. Prevalence of OSA was 77.3%. Twenty-eight (28.9%) patients had hyperaldosteronism. Urinary sodium level was an independent predictor of severity of OSA only in patients with hyperaldosteronism. CONCLUSIONS: The findings suggest that dietary salt is related to the severity of OSA in patients with resistant hypertension and hyperaldosteronism. The results support dietary salt restriction as a treatment strategy for reduction of OSA severity in these patients.
Authors: Takatoshi Kasai; JoAnne Arcand; Johane P Allard; Susanna Mak; Eduardo R Azevedo; Gary E Newton; T Douglas Bradley Journal: J Am Coll Cardiol Date: 2011-11-01 Impact factor: 24.094
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Harneet K Walia; Hong Li; Michael Rueschman; Deepak L Bhatt; Sanjay R Patel; Stuart F Quan; Daniel J Gottlieb; Naresh M Punjabi; Susan Redline; Reena Mehra Journal: J Clin Sleep Med Date: 2014-08-15 Impact factor: 4.062
Authors: Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White Journal: Hypertension Date: 2018-11 Impact factor: 10.190
Authors: Harneet K Walia; Sandra D Griffith; Nancy Foldvary-Schaefer; George Thomas; Emmanuel L Bravo; Douglas E Moul; Reena Mehra Journal: Chest Date: 2016-01-08 Impact factor: 9.410